{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":34,"n_cols":5,"rows_kept":34,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[8,2,8,3],[12,2,12,3],[13,2,13,3],[15,2,15,3],[15,4,15,5],[16,2,16,3],[16,4,16,5],[17,2,17,3],[19,2,19,3],[20,2,20,3],[21,2,21,3],[22,2,22,3],[23,2,23,3],[24,2,24,3],[25,2,25,3],[28,2,28,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA990000812530403321"]
[null,null,"Autore",null,"Giammarco, Carlo"]
[null,null,"Titolo",null,"Disegnare le periferie : il progetto del limite / Carlo Giammarco, Aimaro Isola"]
[null,null,"Pubbl/distr/stampa",null,"Roma : NIS, c1993"]
[null,null,"Descrizione fisica",null,"251 p. : ill. ; 24 cm"]
[null,null,"Collana",null,"La città e il territorio ; 4"]
[null,null,"Locazione",null,"FARBC"]
[{"$nulls":4},"DCATA"]
[null,null,"Collocazione",null,"URB.LE B 1740"]
[{"$nulls":4},"URB.LE B 897"]
[{"$nulls":4},"URB.LE B 929"]
[{"$nulls":4},"210029"]
[null,null,"Lingua di pubblicazione",null,"Italiano"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,"2.","Record Nr.",null,"UNINA9910798302603321"]
[null,null,"Titolo",null,"Frontiers in clinical drug research - CNS and neurological disorders . Volume 4 / / edited by Atta-ur-Rahman"]
[null,null,"Pubbl/distr/stampa",null,"Sharjah, United Arab Emirates : , : Bentham Science Publishers, , [2016]"]
[{"$nulls":4},"©2016"]
[null,null,"ISBN",null,"1-68108-295-0"]
[null,null,"Descrizione fisica",null,"1 online resource (385 pages)"]
[null,null,"Collana",null,"Frontiers in Clinical Drug Research - CNS and Neurological Disorders"]
[null,null,"Disciplina",null,"616.9948"]
[null,null,"Soggetti",null,"Central nervous system"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Includes index."]
[null,null,"Nota di contenuto",null,"Intro -- CONTENTS -- PREFACE -- List of Contributors -- Multiple Sclerosis Drug Therapy: From the Classical Pharmaceutical Down to Cellular and Molecular Approach -- MULTIPLE SCLEROSIS -- Epidemiology, Environmental Agents and Genetics -- Pathogenesis -- Animal Models -- Different Immune System Players on the MS Stage -- T-cells -- B-cells -- Other Immune System Cells and the Innate Immune Response -- Histopathology -- Active Lesions -- Chronic Plaques -- Remyelinated Plaques -- Clinical Features and Diagnostic Criteria -- DISEASE-MODIFYING DRUGS -- Steroids -- Injectable Drugs -- Beta-Interferons -- Glatiramer Acetate -- Oral Drugs -- Teriflunomide -- Dimethyl Fumarate (DMF, BG-12) -- Fingolimod (FTY720) -- Conventional Immunosuppressants -- Cyclophosphamide -- Azathioprine -- Mitoxantrone -- Laquinimod -- Methotrexate -- Biologics (Monoclonal Antibodies) -- Natalizumab -- Alemtuzumab (Campath-1H) -- RECENT EMERGING BIOLOGICAL AND EXPERIMENTAL THERAPEUTICAL APPROACHES -- B-Cells -- Rituximab -- Ocrelizumab and Ofatumumab -- MEDI-551 -- Mast Cells -- Masitinib mesylate -- Cytokines and Chemokines -- Daclizumab -- Tabalumab (LY2127399) -- MOR103 -- Secukinumab -- Tolerogenic Vaccines for MS -- Stem Cells -- Haematopoietic Stem Cells (HSCs) -- Mesenchymal Stem Cells (MSCs) -- Helminths -- Vitamin D -- Remyelination Strategies in MS -- BIIB033 -- rHIgM22 -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- ABBREVIATIONS -- REFERENCES -- Prospective Therapies for Alzheimer Disease: Biomarkers, Clinical Trials and Preclinical Research -- I. INTRODUCTION -- I.1. Background -- I.2. Alzheimer's Disease and the Need for New Drugs -- I.3. The Amyloid "]
[{"$nulls":4},"Cascade Hypothesis (ACH) -- I.4. Correlation among Aβ and other AD Hallmarks -- I.5. Genetics of AD -- I.5.1. APP -- I.5.2. PSEN1/PSEN2 -- I.5.3. APOE -- I.5.4 . APOJ/CLU."]
[{"$nulls":4},"I.5.5. The Role of Genetic Testing in Clinical Care -- II. THE ROLE OF BIOMARKERS IN EARLY DIAGNOSIS AND CLINICAL TRIALS ASSESSMENT -- II.1. Biochemical Markers -- II.1.1. Cerebrospinal Fluid Biomarkers -- II.1.2. Blood Biomarkers -- II.2. Imaging-based Biomarkers -- II.2.1. Structural Magnetic Resonance Imaging -- II.2.2. Diffusion Tensor Imaging -- II.2.3. Functional Magnetic Resonance Imaging -- II.2.4. Proton Magnetic Resonance Spectroscopy -- II.2.5. Fluorodeoxyglucose-Positron Emission Tomography -- II.2.6. Amyloid-Positron Emission Tomography -- II.3. The Continuum of AD: Diagnosis and Prognosis -- II.4. Regulatory Framework -- III. PROSPECTIVE THERAPIES -- III.1. Non-immunologic Therapies -- III.1.1. Clinical Trials -- III.1.2. Preclinical Studies -- III.2. Immunotherapy -- III.2.1. Active Immunotherapy -- III.2.2. Passive Immunotherapy -- CONCLUSION AND FUTURE PERSPECTIVES -- CONFLICT OF INTEREST -- FUNDING -- ACKNOWLEDGMENTS -- REFERENCES -- At the Crossroad between Neuronal Hyperexcitability and Neuroinflammation: New Therapeutic Opportunities for Alzheimer's Disease? -- INTRODUCTION -- 1. BACKGROUND ON AD -- 1.1. APP Processing -- 1.2. Genetics of AD -- 1.3. Clinical Trials &amp -- Treatment Strategies -- 2. PRECLINICAL AVENUES -- 2.1. Neuroinflammation &amp -- Tumor Necrosis Factor-α -- 2.2. Network Hyperexcitability -- 3. CROSS-TALK   BETWEEN   SYNAPTIC   HYPEREXCITABILITY   &amp -- TNF -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- FUNDING -- REFERENCES -- Treatment of Diabetic Neuropathy - Current Possibilities and Perspectives -- INTRODUCTION -- DIABETES MELLITUS -- CHRONIC COMPLICATIONS OF DIABETES MELLITUS -- DIABETIC NEUROPATHY -- ETIOPATHOGENESIS OF DIABETIC NEUROPATHY -- Advanced Glycation End Products -- Oxidative Stress -- Gene Polymorphisms Of Antioxidant Enzymes And Chronic Diabetic Complications."]
[{"$nulls":4},"Polyol Pathway -- Protein Kinase C -- Hexosamine Pathway -- Low C-peptide Concentration -- Proinflammatory Cytokines -- Neurotrophic Factors -- Angiotensin-converting Enzyme -- Kinin B1 Receptor -- TREATMENT OF DIABETIC NEUROPATHY -- Treatment of Diabetes Mellitus - Adequate Compensation -- Supportive and Additional Treatment -- Alpha-lipoic Acid -- Symptomatic Treatment -- Treatment in Experimental and Clinical Studies -- Anti-inflammatory Drugs -- Neurotrophic Factors -- Angiotensin Converting enzyme (ACE) Inhibitors -- Novel Drugs with Antioxidant Functions -- Non-pharmacological Therapy -- inhibitors of Epigenetic Modifications -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- The Now and Tomorrow of Migraine Treatments -- INTRODUCTION -- PATHOPHYSIOLOGICAL OVERVIEW -- ACUTE ATTACK TREATMENT -- Currently Available Drugs -- Nonsteroidal Anti-inflammatory Drugs (NSAIDs) -- Ergot Alkaloids and Triptans -- Combination Regimens -- Narcotic Analgesics -- Hyperbaric Oxygen Therapy -- Medication Overuse Headache -- Novel Targets for Attack Treatment -- CGRP -- NOS Inhibition -- TRP Channels -- Glutamate Receptors -- PACAP-38 -- Cannabinoids -- The Parenchymal Inflammatory Cascade -- PROPHYLACTIC TREATMENT -- Currently Available Drugs -- Antiepileptics -- Antidepressants -- Beta Blockers -- Calcium Channel Blockers -- Glutamate Receptor Antagonists -- Triptans -- Novel Targets for Prophylactic Treatment -- CGRP -- NOS Inhibition -- Gap Junction Blockers -- Renin-Angiotensin System -- Acid Sensing Ion Channels -- Botulinum Neurotoxin -- CONCLUDING "]
[{"$nulls":4},"REMARKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- The Now and Tomorrow of Ischemic Stroke Treatment -- ADVANCES IN TREATMENT OF ACUTE ISCHEMIC STROKE -- Recanalization/Reperfusion -- Neuro-Glial Protection -- Prevention of Secondary Complications."]
[{"$nulls":4},"ADVANCES IN SECONDARY PROPHYLAXIS OF ISCHEMIC STROKE -- CONCLUDING REMARKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- SUBJECT INDEX."]